Job Information
Organisation/Company: Chiba Cancer Center
Department: Division of Molecular Carcinogenesis
Research Field: Technology, Biological sciences, Medical sciences, Agricultural sciences, Anthropology, Ethics in health sciences, Pharmacological sciences, Environmental science, Neurosciences, Chemistry
Researcher Profile: Recognised Researcher (R2)
Application Deadline: 31 Mar 2027 - 23:59 (UTC)
Country: Japan
Type of Contract: Permanent
Job Status: Not Applicable
Hours Per Week: See description
Is the job funded through the EU Research Framework Programme? Not funded by a EU programme
Is the Job related to staff position within a Research Infrastructure? No
Offer Description
Background of the recruitment and description of the project
Our laboratory focuses on refractory adult and pediatric cancers, aiming to elucidate mechanisms of tumorigenesis, identify novel molecular targets, and develop innovative therapeutic strategies.
We are particularly interested in the RUNX family of transcription factors (RUNX1/2/3), which play key roles in tumor growth, metastasis, and immune evasion. Based on this concept, we have developed a novel therapeutic strategy termed the “CROX strategy” (Cluster Regulation Of RUNX).
Our research spans from basic molecular mechanisms to translational applications, including preclinical validation using patient-derived organoids and the chick chorioallantoic membrane (CAM) model. We are also developing a novel RUNX inhibitor, Chb-M', with strong therapeutic potential. The Division of Oncogenic Regulation at the Chiba Cancer Center Research Institute is seeking a highly motivated postdoctoral researcher to join our team in cancer biology and drug discovery research.
Details of the business
The Division of Oncogenic Regulation originated from the former Division of Biochemistry. Following the transfer of Dr. Takehiko Kamijo to Saitama Cancer Center, Dr. Yoshitaka Fudetaka (currently Director of the Research Institute, Chiba Cancer Center) joined as Division Chief from the National Cancer Center. In 2022, Yasuhiko Kamikubo was appointed Division Chief from Kyoto University. Since then, the division has been actively advancing research in close collaboration with Chiba Cancer Center Hospital. Our research focuses on refractory adult and pediatric cancers, with the goal of understanding how cancers develop, identifying new therapeutic targets, and creating innovative treatments. We study a wide range of cancers, including leukemia and major solid tumors, and aim to build a foundation for next-generation precision medicine based on shared mechanisms across cancer types. We have found that RUNX transcription factors (RUNX1/2/3) are frequently overexpressed in many cancers and contribute to tumor growth, metastasis, and immune evasion. Based on this discovery, we proposed the "CROX strategy" (Cluster Regulation Of RUNX), a new approach that enables comprehensive suppression of RUNX activity. Preclinical studies have shown promising results, suggesting its potential as a broadly applicable cancer treatment strategy. Currently, we are evaluating a novel RUNX inhibitor, Chb-M', using patient-derived organoids and the chick CAM model, with the aim of advancing its application in personalized cancer therapy.
Work content and job description
Responsibilities
- Investigate the molecular mechanisms underlying tumorigenesis in adult and pediatric cancers
- Analyze RUNX-dependent transcriptional regulation (RUNX1/2/3) and its role in cancer progression
- Conduct drug discovery research based on the CROX strategy (Cluster Regulation Of RUNX)
- Evaluate the mechanism of action and therapeutic efficacy of a novel RUNX inhibitor (Chb-M')
- Perform preclinical studies using cancer cell lines, mouse models, patient-derived organoids, and CAM assays
- Promote collaborative and translational research in partnership with clinical teams
- Prepare scientific manuscripts and present research findings at conferences
Assigned department
Existing departments
Work location
Address
260-8717 Chiba 666-2 Nitona-cho, Chuo-ku, Chiba 260-8717, Japan
Number of hired
Number of hired: 1 person(s)
Hiring date: 2026-06-01 00:00:00
Starting date: 2026-06-01 00:00:00
Where to apply
Website: https://jrecin.jst.go.jp/seek/SeekJorDetail?fn=0&ln=1&id=D126040068&ln_jor=1
Additional Information
Benefits
Compensation
Hourly wage: 1750 yen - 3000 yen
Working hours: 08:30-17:15
Break time: 12:00-13:00
Holidays: a five-day workweek (two days off per week)
Overtime and other explanations: Under the discretionary labor system, employees are deemed to have worked 8 hours per day.
Employment type: Contract employee
Contract period: Nontenured
Contract period description: 2~3 years
Probationary period: Probationary period present
Probationary period description: Trial period: 3 month
Various systems
Insurance
Measures for preventing passive smoking at the workplace
Supplementary explanation of compensation
Work Location(s)
Number of offers available: 1
Company/Institute: Chiba Cancer Center
Country: Japan
City: Chiba
Contact
City: Chiba
